Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
Doctors are testing a new treatment called daratumumab for patients with multiple myeloma. This treatment uses something called monoclonal antibodies to try and kill any cancer cells left in the body after chemotherapy. It's only in the second stage of testing, but it could be promising for patients who need more options to fight their cancer.
Doctors are testing a new treatment called daratumumab for patients with multiple myeloma. This treatment uses something called monoclonal antibodies to try and kill any cancer cells left in the body after chemotherapy. It's only in the second stage of testing, but it could be promising for patients who need more options to fight their cancer.
*Third Opinion AI Generated Synopsis
Trial Summary
This phase II trial studies how well daratumumab after a stem cell transplant works in treating patients with multiple myeloma. Monoclonal antibodies, such as daratumumab, may kill cancer cells that are left after chemotherapy.
This phase II trial studies how well daratumumab after a stem cell transplant works in treating patients with multiple myeloma. Monoclonal antibodies, such as daratumumab, may kill cancer cells that are left after chemotherapy.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: